← Back to patent-cliff list
昔萘酸沙美特罗
Tier C — Watch / tradeSalmeterol xinafoate
葛兰素史克
Originator
1994
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ADRB2
Brand：Serevent Diskus、Salmetedur、Serevent Diskhaler、Inaspir、Aeromax、Beglan、Serevent
Indications (approved)：慢性阻塞性肺疾病、哮喘、运动诱发哮喘、支气管痉挛
Regional status
US
批准上市
1994-02-04
EU
-
China
批准上市
1998-01-01
Japan
批准上市
2004-02-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Salmeterol xinafoate?
Approved indications include: 慢性阻塞性肺疾病, 哮喘, 运动诱发哮喘, 支气管痉挛.
When does the Salmeterol xinafoate patent expire?
No public expiry year is available for Salmeterol xinafoate yet; this page updates once verified.
How do I get a quote for Salmeterol xinafoate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25